Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin Plus Doxorubicin in Leiomyosarcoma
NCT05099666Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2022
- Primary completion
- Dec 2026
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in soft tissue sarcoma (STS), leiomyosarcoma (LMS), sponsored by Massachusetts General Hospital. Started Feb 2022; status: active, not recruiting.
02
Drugs
lurbinectedin
03
Conditions
soft tissue sarcoma (STS)leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT05099666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099666.